NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

Search

Fortive Corp

Atidarymo kaina

SektoriusTechnologijų sektorius

55.75 2.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

54.2

Max

56.1

Pagrindiniai rodikliai

By Trading Economics

Pajamos

137M

192M

Pardavimai

95M

1.1B

P/E

Sektoriaus vid.

34.837

81.314

Dividendų pajamingumas

0.51

Pelno marža

17.06

Darbuotojai

10,000

EBITDA

11M

225M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+9.33% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.51%

2.43%

Kitas uždarbis

2026-04-30

Kitas dividendų mokėjimo data

2026-06-26

Kita Ex Dividend data

2026-05-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-576M

18B

Ankstesnė atidarymo kaina

53.51

Ankstesnė uždarymo kaina

55.75

Naujienos nuotaikos

By Acuity

31%

69%

85 / 375 reitingas Technology

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Fortive Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-31 23:31; UTC

Karštos akcijos

Stocks to Watch: Nike, RH, NCino

2026-03-31 22:35; UTC

Uždarbis

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026-04-01 00:00; UTC

Įsigijimai, susijungimai, perėmimai

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026-03-31 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026-03-31 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026-03-31 23:33; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026-03-31 23:21; UTC

Uždarbis

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026-03-31 23:14; UTC

Rinkos pokalbiai
Uždarbis

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026-03-31 23:12; UTC

Rinkos pokalbiai

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss Widens >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026-03-31 21:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026-03-31 21:36; UTC

Rinkos pokalbiai

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026-03-31 21:35; UTC

Uždarbis

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026-03-31 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026-03-31 21:33; UTC

Uždarbis

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026-03-31 21:32; UTC

Uždarbis

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026-03-31 21:28; UTC

Uždarbis

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026-03-31 21:26; UTC

Uždarbis

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026-03-31 21:25; UTC

Uždarbis

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026-03-31 21:24; UTC

Rinkos pokalbiai
Uždarbis

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026-03-31 21:22; UTC

Uždarbis

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026-03-31 21:22; UTC

Uždarbis

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026-03-31 21:21; UTC

Uždarbis

Nike's Digital Channel Still Too Promotional, CFO Says

2026-03-31 21:20; UTC

Uždarbis

Nike CEO: Converse Remains Important to Portfolio

Akcijų palyginimas

Kainos pokytis

Fortive Corp Prognozė

Kainos tikslas

By TipRanks

9.33% į viršų

12 mėnesių prognozė

Vidutinis 60.44 USD  9.33%

Aukščiausias 65 USD

Žemiausias 51 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fortive Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

10 ratings

2

Pirkti

6

Laikyti

2

Parduoti

Techninis įvertinimas

By Trading Central

66.84 / 69.85Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

85 / 375 reitingas Technologijų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fortive Corp

Fortive Corporation designs, develops, manufactures, and services professional and engineered products, software, and services in the United States, China, and internationally. It operates in three segments: Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. The Intelligent Operating Solutions segment provides advanced instrumentation, software, and services, including electrical test and measurement, facility and asset lifecycle software applications, and connected worker safety and compliance solutions for manufacturing, process industries, healthcare, utilities and power, communications and electronics, and other industries. This segment markets its products and services under the ACCRUENT, FLUKE, GORDIAN, INDUSTRIAL SCIENTIFIC, INTELEX, PRUFTECHNIK, and SERVICECHANNEL brands. The Precision Technologies segment offers electrical test and measurement, sensing and material technologies for industrial, power and energy, automotive, medical equipment, food and beverage, aerospace and defense, semiconductor, and other general industries under the ANDERSON-NEGELE, GEMS, SETRA, HENGSTLER-DYNAPAR, QUALITROL, PACIFIC SCIENTIFIC, KEITHLEY, and TEKTRONIX brand names. The Advanced Healthcare Solutions segment provides critical workflow solutions comprising instrument sterilization, instrument tracking, design and manufacture of cell therapy equipment, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions under the ASP, CENSIS, CENSITRAC, EVOTECH, FLUKE BIOMEDICAL, INVETECH, LANDAUER, PROVATION, RAYSAFE, and STERRAD brands. Fortive Corporation was incorporated in 2015 and is headquartered in Everett, Washington.
help-icon Live chat